# Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection

> **NCT00006178** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 12 (actual)

## Conditions studied

- Kidney Failure

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Thymoglobulin

## Key facts

- **NCT ID:** NCT00006178
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006178, "Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00006178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*